Tuesday, July 1, 2025 7/1/2025

TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity

Award Number: R01CA253285
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2021
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity - ABSTRACT Spontaneous T cell pressure against an evolving tumor is a conserved mechanism of anti-tumor immune control. On the other hand, immune therapies directed to alleviate paralyzing T cell dysfunction within solid tumors only benefits a small proportion of patients with metastatic disease. The field is in desperate need for the development of complementary therapies capable of enhancing sustained T cell-mediated control of primary and metastatic tumor growth. However, myeloid cells within tumors present a substantial barrier towards overcoming the immune dysfunction present in most cancers. Here, we demonstrate that recognition of commensal bacteria through TLR5 signaling results in sustained myeloid dysfunction and impaired response to PD-L1 blockade. TLR5 signaling broadly impairs myeloid function, resulting in infiltration of tumors with poorly functional T cells. In TLR5 KO mice, PD-L1 blockade achieves significantly increased overall survival and leads to durable and long-term remission for mice bearing aggressive ovarian tumors. The effect of TLR5 signaling is recapitulated in non-responsive melanoma and breast tumor models, suggesting that this signaling pathway is a conserved mechanism of immune suppression and failure for PD-L1 blockade. Mechanisms underlying myeloid dysfunction and failure of PD-L1 blockade have largely focused upon interactions between tumors and immune cells. However, our data implicate a mechanism whereby recognition of commensal bacteria by TLR5-expressing immune cells initiates myeloid dysfunction and failure of PD-L1 blockade. Based upon these data, inhibition of TLR5 signaling emerges as a means of restoring anti-tumor T cell function across a broad range of tumor types. However, because TLR5 signaling is canonically associated with activation of adaptive immunity in other settings, it is critical to understand how TLR5 signaling impairs myeloid function within the tumor microenvironment. The overarching goal is to define how commensal microorganisms impair anti-tumor immunity and response to PD-L1 blockade. Here, we will test the hypothesis that chronic encounter with microbiome-derived TLR5 ligands and autocrine amplification of IL-6 polarize TLR5-expressing myeloid cells within the tumor microenvironment (TME). This results in impaired ability of myeloid cells to prime and/or recall tumor-reactive T cells and subsequent failure of PD-L1 blockade. Aim 1 will define how TLR5 signaling on myeloid cells affects tumor growth and response to PD-L1 blockade. Aim 2 will determine how TLR5 signaling impairs myeloid function. Aim 3 will leverage in vivo labelling of commensal microorganisms to establish how encounters between commensal microorganisms and TLR5 expressing immune cells within the tumor microenvironment impair anti- tumor immune function. Mechanistically, very little is known as to how the microbiome negatively impacts host anti-tumor immune function. The studies proposed herein will fill this gap in knowledge, providing critical insight into how host-microbiome crosstalk negatively impacts anti-tumor immunity and response to PD-L1 blockade.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $410,973 )
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	000	5	2/19/2025	NON-COMPETING CONTINUATION	$369,875
2025	2025	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	001	5	5/23/2025	NON-COMPETING CONTINUATION	$41,098
														Subtotal = $410,973

Issue Date FY: 2024 ( Subtotal = $397,110 )
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	001	4	4/17/2024	NON-COMPETING CONTINUATION	$20,902
2024	2024	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 EMMET ST N	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	000	4	2/2/2024	NON-COMPETING CONTINUATION	$376,208
														Subtotal = $397,110

Issue Date FY: 2023 ( Subtotal = $402,753 )
2023	2023	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	000	3	2/27/2023	NON-COMPETING CONTINUATION	$402,753
														Subtotal = $402,753

Issue Date FY: 2022 ( Subtotal = $408,401 )
2022	2022	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	001	2	4/28/2022	NON-COMPETING CONTINUATION	$33,339
2022	2022	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	000	2	1/19/2022	NON-COMPETING CONTINUATION	$375,062
														Subtotal = $408,401

Issue Date FY: 2021 ( Subtotal = $401,968 )
2021	2021	RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA	1001 N EMMET ST	CHARLOTTESVILLE	VA	22903	CHARLOTTESVILLE CITY	USA	Cancer Biology Research	000	1	2/19/2021	NEW	$401,968
														Subtotal = $401,968

Grand Total All Awards = $2,021,205

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity

Award Number: R01CA253285

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2021

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer